Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
<h4>Objective</h4> The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have been demonstrated in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer (BC). It is, however, necessary to evaluate the value of T-D...
Main Authors: | Demin Shi, Xueyan Liang, Yan Li, Lingyuan Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449172/?tool=EBI |
Similar Items
-
Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
by: Demin Shi, et al.
Published: (2023-01-01) -
Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
by: Lang Y, et al.
Published: (2022-12-01) -
Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01) -
Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer
by: Jiangping Yang, et al.
Published: (2023-05-01) -
Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
by: Mei Zhan, et al.
Published: (2023-06-01)